Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis.

Clin Mol Hepatol · 2026 · PMC12835736 · PMID 41215582

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The effect size appeared consistent among metformin users (HR 0.81, 95% CI 0.68–0.97) and aspirin users (HR 0.84, 95% CI 0.71–1.01), although the latter did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.